QuarterlyIQ Insights · ABBV
Earnings
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Next earnings
Average absolute move on past earnings days.
Annualized — recent baseline volatility.
Guidance track record
Of the last 8 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings events
Earnings prints and pre-announcements detected in the SEC filing stream.
- 2026-04-29earnings miss
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 29, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
negative80 - 2026-04-03earnings miss
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
negative80 - 2026-02-04earnings miss
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 4, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
negative80 - 2026-01-07earnings miss
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures.…
negative80 - 2025-10-31earnings miss
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
negative80 - 2025-10-03earnings miss
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2025 have not been finalized and are subject to our financial statement closing procedures.…
negative80 - 2025-07-31earnings inline
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
neutral67 - 2025-07-03earnings inline
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
neutral67 - 2025-04-25earnings inline
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 25, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
neutral67 - 2025-04-03earnings inline
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
neutral67 - 2025-01-31earnings inline
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: January 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
neutral67 - 2025-01-06earnings inline
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures.…
neutral67 - 2024-10-30earnings inline
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 30, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
neutral67 - 2024-10-03earnings inline
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2024 are expected to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2024 have not been finalized and are subject to our financial statement closing procedures.…
neutral67 - 2024-07-25earnings inline
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 25, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
neutral67 - 2024-07-03earnings inline
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis, representing an unfavorable impact of $0.52 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2024 have not been finalized and are subject to our financial statement closing procedures. The…
neutral67
EPS / revenue actuals and consensus per quarter (8-quarter history) need a mart view over AlphaVantage EARNINGS + EARNINGS_ESTIMATES — the backend ingest exists but isn't exposed to the frontend yet. Once that lands we can show beat/miss, surprise size, and forward consensus on this tab.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.